Clinical trial NCT06143774: Study of TRX-920 for Patients With Advanced Solid Tumors
Official title: A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TRX-920 Oral Gel (10 mg and 30 mg) in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumor
Keywords: TRX-920 Oral Gel
SN38
Lead sponsor: TaiRx, Inc.
Sponsor class: INDUSTRY
First posted: 2023-11-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Dose-finding Study using 3+3 design.
Primary purpose: TREATMENT

Brief summary: The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that directly contains SN38 instead of Irinotecan. A series of biology and animal studies have demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects compared to Irinotecan.

Detailed description: This is the first study in which the study drug TRX-920 Oral Gel is being given to humans. However, as a metabolite of Irinotecan, SN38 has proved its effectiveness in the treatment of colorectal and pancreatic cancer. TRX-920 also showed its effect of anti-tumor in various cancer cell lines and animal models. The purposes of this study are to find the highest dose of the study drug that can be given without causing significant side effects, the side effect of the study drug, the concentration of the study drug in the blood, and the effect on your specific cancer.

The clinical study will be conducted in Taiwan. The drug used in this study is an investigational product (TRX-920 Oral Gel) which is provided free of charge by TaiRx, Inc. (a pharmaceutical company in Taiwan, and is the sponsor of this study), and is a potential oral anti-cancer therapy for patients suffering from various cancers.

Eligibility criteria: Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for enrollment in the study:

1. Signed and dated informed consent form
2. Histologically and cytologically confirmed advanced solid tumor malignancies that are refractory to standard therapy or have no accepted standard therapy.
3. Solid tumors that are measurable or evaluable as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion).
4. Female or male, 18 years of age or older.
5. ECOG performance status 0 or 1.
6. QTcF ≤ 480 ms at screening.

Exclusion Criteria:

1. Patients with homozygous or compound heterozygous genotypes for UGT1A1\*28 and \*6 alleles (e.g., \*28/\*28, \*6/\*6, \*6/\*28).
2. Clinically significant comorbidity such as unstable angina, congestive heart failure (NYHA Grade III or IV), uncontrolled hypertension (\>160/100 mmHg despite optimal medical treatment), chronic obstructive pulmonary disease (COPD) with frequent exacerbations, refractory asthma, inflammatory bowel disease or intestinal obstruction.
3. Acute myocardial infraction or cerebrovascular accident (CVA) within 6 months prior the first dose of study drug.
4. Central nervous system (CNS) metastasis or seizure disorder due to underlying malignancy except those who have been treated and have stable CNS metastases or are asymptomatic.
5. AIDS-defining opportunistic infections within the past 12 months.
6. HBV infection (positive HBsAg) except for carrier of inactive HBV as defined by negative HBeAg with normal ALT and HBV DNA \< 2,000 IU/mL or HCV infection (positive anti-HCV antibody) except for those with undetectable HCV RNA.
7. Inadequate bone marrow reserve, hepatic or renal function as defined by any of the following laboratory values:

   1. absolute neutrophil count (ANC) \< 1500/µL
   2. platelet count \< 90,000/µL
   3. hemoglobin \< 9 g/dL
   4. total bilirubin \> 1.5\*the upper limit of normal (ULN)
   5. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3\*ULN if no hepatic metastases are present; \> 5\*ULN if hepatic metastases are present
   6. Non-indexed eGFR \< 60 mL/min (formula in Appendix 4)
8. Toxicities resulting from prior therapy or surgical procedures not yet resolved to ≤ NCI CTCAE v5.0 Grade 1 with the exception of alopecia, skin hyperpigmentation or hypopigmentation or grade 2 toxicity with prior approval of the Medical Monitor.
9. Major surgical procedures (as defined by Investigator) within 4 weeks prior to the first dose of study drug or any ongoing post-operative complications.
10. Receiving any radiotherapy within 3 months
11. Receiving any (investigational or approved) anti-cancer therapy (including chemotherapy or targeted therapy) within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study drug
12. A history of apparent allergic reactions to irinotecan injection (dosed with prior treatment with prophylactic drug)
13. If female, is pregnant or breastfeeding
14. If men or women with childbearing potential, unwilling to use effective contraceptive methods during the study and for at least 3 months (men) or 1 month (women) after the last dose of study drug. Effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization, or a partner who is sterile.
15. Receiving live attenuated vaccine within 28 days prior to the first dose of study drug.
16. Life expectancy \< 3 months.
17. Other prior or ongoing condition(s) that, in the opinion of the investigator, could affect the safety of the subject, compromise the subject's ability to comply with the study requirements or impair the assessment of study results.

Primary outcomes:
measure: Maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of TRX-920 Oral Gel
timeFrame: the first 4 weeks post the first dose
measure: Frequency, type, severity and relationship to study drug of adverse events (AEs) of TRX-920 Oral Gel
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary outcomes:
measure: Drug exposure and human pharmacokinetics (Cmax) of SN38 derived from plasma concentration-time profiles
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Drug exposure and human pharmacokinetics (Tmax) of SN38 derived from plasma concentration-time profiles
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Drug exposure and human pharmacokinetics (MRT) of SN38 derived from plasma concentration-time profiles
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Drug exposure and human pharmacokinetics (AUC) of SN38 derived from plasma concentration-time profiles
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Drug exposure and human pharmacokinetics (terminal half-life) of SN38 derived from plasma concentration-time profiles
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Objective response rate (ORR) per RECIST v1.1
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Disease control rate (DCR) per RECIST v1.1
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
measure: Duration of response (DOR) per RECIST v1.1
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days), assessed up to 24 months
measure: Time to tumor progression (TTP) per RECIST v1.1
timeFrame: Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days), assessed up to 24 months
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Tainan
country: Taiwan
facility: National Cheng-Kung University Hospital
city: Taipei
country: Taiwan
facility: Taipei Medical University Hospital
Study officials:
affiliation: China Medical University, Taiwan
name: Li-Yuan Bai, M.D.
role: PRINCIPAL_INVESTIGATOR
References: